[Correspondence] Clinical implications and biomarkers in the PACT-21 CASSANDRA trial

The PACT-21 CASSANDRA trial,1 reported by Michele Reni and colleagues, involving 260 patients with mixed resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC), concluded that “preoperative PAXG [cisplatin, nab-paclitaxel, capecitabine, and gemcitabine] should be considered as